Company
Investment-firm
Last deal
Amount
Stage
Date
all rounds
Total amount
Financing round
General
About Company
Industry
Sector :
Subsector :
Also Known As
founded date
founders
Number of employees
Company Type
Last funding type
IPO status
Contacts
location
Contact Email
Phone number
Website URL
Similar Companies1000
Certa Therapeutics
Cura Therapeutics is a biotechnology company that develops drugs to treat fibrotic diseases.
Sector
Subsector
Keywords
Location
total rounds
total raised
ARTHEx Biotech
ARTHEx Biotech S.L. develops antisense RNA treatments against genetic diseases.
Sector
Subsector
Location
total rounds
total raised
Avrobio
Avrobio is a clinical-stage gene therapy company developing advanced treatments for cancer and rare diseases.
Sector
Subsector
Keywords
Location
total rounds
total raised
Audentes Therapeutics
Astellas Gene Therapies is a biotechnology company developing genetic medicines with the potential to transform patient outcomes.
Sector
Subsector
Location
total rounds
total raised
M&A Details1
Transaction name
Acquired by
Syncona Partners LLP
announced date
price
Financials
Funding Rounds8
Number of Funding Rounds
Money Raised
Their latest funding was raised on 12.07.2022. Their latest round Post-IPO Equity
Investments1
Nanostream Inc.
Nanostream Inc. provides high-throughput microfluidic analytical systems.
Sector
Subsector
Keywords
Location
total rounds
total raised
Co-Investors
Investors6
Number of lead investors
Number of investors
OUP (Osage University Partners)
Osage University Partners (OUP) is a venture capital fund that invests exclusively in startups commercializing university research.
Sector
Subsector
Keywords
Location
count Of Investments
count Of Exists
Bill Harrington
William Harrington serves as Managing Partner at Osage Partners. Bill joined Osage University Partners in 2012. He previously served as a Partner at Three Arch Partners, a venture capital firm with over $1 billion under management. During Bill’s twelve years at Three Arch, he focused on medical device, biotechnology, and healthcare service investing. Bill led investments in and served as a director of nearly twenty healthcare companies, a number of which had their origin as university spinouts. He most recently served on the boards of Cameron Health, Baxano, Voyage Medical, Nevro Corporation, APT Pharmaceuticals, and Centerre Healthcare. Prior to entering venture capital in 1999, Bill spent a decade as an interventional radiologist, working with promising new imaging technologies, medical devices, and minimally invasive surgical procedures. Bill holds an MD from Harvard Medical School, an MBA from UC Berkeley, and a BS in Biology and Chemistry from Tufts University. Bill is a CFA charterholder.
current job
SR One
SR One Capital Management is a biotech venture capital firm.
Sector
Subsector
Keywords
Location
count Of Investments
count Of Exists
Jill Carroll
Jill joined SR One in 2011 with a background in biotech partnering and commercial development. Prior to SR One, Jill was responsible for Corporate Development at Dynavax Technologies, where she was involved in multiple pharma partnering deals as well as substanial private and public financings. Previously, Jill was a consultant specializing in health care at Clearview Projects and Mercer Management Consulting. Jill received her BS in Chemistry from Duke University, and her MS in Biochemistry, Cellular and Molecular Biology from Johns Hopkins University.
current job
InterWest Partners
InterWest is a venture capital firm that invests in healthcare and IT companies.
Sector
Subsector
Keywords
Location
count Of Investments
count Of Exists
Arnie Oronsky
Dr. Arnie Oronsky has been with InterWest's life sciences team since 1994. He is a board member of Amplimmune, Applied Genetic Technologies Corporation (AGTC), Arcion, Drais Pharmaceuticals, Dynavax Technologies (DVAX), Integrated Diagnostics, MacroGenics, RadioRX, TESARO and USDS. As a Ph.D. in immunology and senior lecturer at the Department of Medicine at Johns Hopkins Medical School, Arnie brings a deep understanding of medical research to finding and investing in successful life sciences companies. Prior to joining InterWest, Arnie was vice president for discovery research of the Lederle Laboratories division of American Cyanamid Company where he directed the research for new drugs. Arnie received a Ph.D. in immunology from Columbia University and has published more than 125 articles in scientific journals.
current job
People
Founders6
Nicholas Muzyczka
Nicholas Muzyczka is a Co-Founder at Lacerta Therapeutics.
current job
organization founded
Nicholas Muzyczka
R. Jude Samulski
Richard Samulski, Ph.D. serves as the President of Chatham Therapeutics LLC. Samulski has been Scientific Co-Founder of Asklepios Biopharmaceutical, Inc. since 2003 and served as its Chief Executive Officer. In 1993, Samulski co-founded an AAV-based gene therapy company Merlin. He also co-founded Applied Genetic Technologies Corporation in 1999. He also serves as a gene therapy consultant to the FDA. Through the UNC gene therapy center, Samulski has produced within an academic setting an FDA approved AAV clinical vector used to treat children with the neurological disorder of Canavan's disease. He serves as Professor of Pharmacology of The University of North Carolina. Samulski served at AAV for 25 years. Samulski has been Director of the University of North Carolina Gene Therapy Center for eight years. He serves as a Member of Scientific Advisory Board of Ceregene, Inc. He served at AAV biology as a Member of the scientific advisory board of Avigen, a new AAV research company. Samulski has over 20 patents filed or issued in the area of AAV vectors. Samulski served as a Member of the Recombinant DNA Advisory Committee (RAC), a committee tasked with assisting the FDA with approving or disapproving gene therapy clinical trials in the United States. Samulski is a recipient of the President's Distinguished Research Award from the University of Pittsburgh. He completed Post-Doctoral training at Princeton. Samulski's graduate work (1978-82) demonstrated the first use of AAV as a viral vector and culminated in the first US patent involving non-AAV genes inserted into AAV. Samulski received his PhD in Medical Microbiology and Immunology from the University of Florida and his research focuses on the study of the dependent parvovirus adeno-associated virus (AAV)
current job
organization founded
R. Jude Samulski
William Hauswirth
Hauswirth received his B.S. in Chemistry from Stanford University and his Ph.D in Physical Chemistry from Oregon State University. After an NIH Fellowship in the Biochemistry Department at Johns Hopkins University, he joined that department as an Assistant Professor. In 1976, he joined the faculty of Molecular Genetics and in 1985 the Ophthalmology faculty at the University of Florida. While at UF. Hauswirth is, in part, responsible for determining the mechanism of replication of adeno-associated virus (AAV) DNA and the discovery of mitochondrial DNA heteroplasmy in mammals. More recently he collaborated on the first successful rescue of a dominant genetic disease in animals (ribozyme treatment in a Retinitis Pigmentosa model in rats) and the first restoration of vision for a recessive retinal disease (congenitally blind Briard dogs). His current interests involve the delivery and testing of potentially therapeutic genes for Retinitis Pigmentos.
current job
organization founded
William Hauswirth
Barry Byrne
Barry Byrne joined University of Florida as Professor in 1997.Byrne is a Pediatric Cardiologist clinician and Associate chair of the Congenital Heart Center at UF. He is a professor in pediatrics and molecular genetics and is currently the director of the University of Florida Powell Gene Therapy Center. His research is aimed to help those affected by genetic muscular diseases and he is currently the PI on multiple clinical trials for this effort. His primary involvement lies with disorders such as Pompe, Barth, muscular dystrophy, and the associated cardiomyopathy of these diseases. Byrne obtained his B.S. in Chemistry from Denison University in Ohio, his M.D. and Ph.D. from the University of Illinois, and completed his residency and fellowship training at Johns Hopkins University in Maryland. He was an Assistant Professor at Hopkins after completing his training before coming to the University of Florida in 1997.
current job
organization founded
Barry Byrne